LSE:HVO (hVIVO Plc)

About HVO

hVIVO plc is a United Kingdom-based specialist contract research organization (CRO). The Company is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. It provides end-to-end early clinical development services to its client base, which includes global biopharma companies. It offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. It offers additional clinical field trial services, such as patient recruitment and clinical trial site services. It runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.
  • hVIVO Plc (LSE: HVO) Latest News

    Investing Articles

    2 under-the-radar growth stocks I’ve just bought for my Stocks and Shares ISA

    Our writer highlights a couple of relatively obscure investments he's recently been making to build up his Stocks and Shares…

    Read more »

    Engineer Project Manager Talks With Scientist working on Computer
    Investing Articles

    Is hVIVO still a top UK stock for growth after today’s full-year results? 

    This UK stock has risen roughly 370% over the last five years. But Edward Sheldon believes it has the potential…

    Read more »

    British Pennies on a Pound Note
    Investing Articles

    1 ex-penny stock I’d buy in March while it is 27p

    Ben McPoland highlights hVIVO (AIM:HVO), a fast-growing former penny stock that he's been buying for his ISA portfolio.

    Read more »

    Investing Articles

    Here’s how I’d start investing in UK stocks with just £500

    Our writer explains how he would start investing by finding companies that are familiar through experience or everyday observations.

    Read more »

    Young Caucasian woman holding up four fingers
    Investing Articles

    How I built £4,000 of passive income starting with £0

    Getting started with passive income is easier than most people think. Even starting with nothing, a safety net is still…

    Read more »

    Investing Articles

    2 penny stocks with enormous potential

    Edward Sheldon has been scanning the market for penny stocks with a lot of potential. And he believes these two…

    Read more »

    Content white businesswoman being congratulated by colleagues at her retirement party
    Investing Articles

    This is the best-performing FTSE 100 stock of the last 40 years

    The best FTSE 100 stock of the last 40 years may surprise readers. To be able to retire, I want…

    Read more »

    One English pound placed on a graph to represent an economic down turn
    Investing Articles

    Here’s a 28p FTSE stock that has the potential to reach £1

    Our writer takes a look at a high-flying FTSE small-cap stock that is up once again today following a bullish…

    Read more »

    Arrow symbol glowing amid black arrow symbols on black background.
    Small-Cap Shares

    3 high-growth penny stocks to consider buying for 2024

    Edward Sheldon's been scanning the market for penny stocks with significant potential. Here are three he likes for 2024.

    Read more »

    Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
    Investing Articles

    1 hot UK growth stock I’m buying right now

    I've more than doubled my money on this UK growth stock. But with a 948% boost to earnings, I think…

    Read more »

    Athlete preparing to run on start line in a lane numbered '2023'
    Investing Articles

    “My best-performing UK stock in 2023 has been…”

    Four very different UK stocks owned by a Fool.co.uk contractor are highlighted for their performance in 2023 so far.

    Read more »

    A GlaxoSmithKline scientist uses a microscope
    Investing Articles

    This ex-penny stock just paid its first ever dividend. Here’s how much

    Ben McPoland takes a look at a former penny stock whose revenue has just jumped 52% after securing a handful…

    Read more »